Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders - Trial NCT05792540
Access comprehensive clinical trial information for NCT05792540 through Pure Global AI's free database. This Phase 2 trial is sponsored by Tanta University and is currently Recruiting. The study focuses on Depressive Disorder. Target enrollment is 75 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tanta University
Timeline & Enrollment
Phase 2
Jun 06, 2023
Mar 20, 2025
Primary Outcome
• The primary endpoint is the change in Hamilton Rating Scale
Summary
Major depressive disorder (MDD) is a significant cause of disability that affects
 approximately 16% of the world's population and is associated with chronic inflammation.
 Although the mechanisms of MDD have not yet been clearly elucidated, NLRP3 inflammasomes have
 been implicated in the pathogenesis of depression.NLRP3 inflammasome is an intracellular
 multiprotein complex that consists of nod-like receptor protein 3, an adaptor protein, and a
 procaspase-1 precursor. It is well known that a variety of danger signals, such as
 pathogen-associated molecular patterns and danger-associated molecular patterns can activate
 NLRP3 inflammasome
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05792540
Non-Device Trial